KBC Group NV Boosts Position in Kenvue Inc. (NYSE:KVUE)

KBC Group NV boosted its position in Kenvue Inc. (NYSE:KVUE) by 114.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 966,160 shares of the company’s stock after purchasing an additional 514,580 shares during the period. KBC Group NV owned about 0.05% of Kenvue worth $22,348,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Riverview Trust Co bought a new stake in shares of Kenvue during the 3rd quarter valued at $30,000. Ashton Thomas Securities LLC purchased a new position in Kenvue during the third quarter valued at $35,000. Studio Investment Management LLC grew its holdings in Kenvue by 52.1% during the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock valued at $45,000 after purchasing an additional 845 shares during the period. Deseret Mutual Benefit Administrators increased its position in Kenvue by 49.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after buying an additional 651 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in shares of Kenvue in the second quarter worth about $61,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Trading Up 1.0 %

KVUE opened at $23.84 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock’s 50 day moving average price is $22.75 and its 200-day moving average price is $20.65. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.13. The stock has a market cap of $45.70 billion, a price-to-earnings ratio of 43.34, a P/E/G ratio of 2.10 and a beta of 1.36.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business’s revenue was down .4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.31 earnings per share. On average, equities analysts forecast that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date is Wednesday, November 13th. Kenvue’s payout ratio is 149.09%.

Wall Street Analyst Weigh In

KVUE has been the subject of a number of recent analyst reports. Royal Bank of Canada lowered shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 price target for the company. in a research report on Tuesday, September 24th. Bank of America raised their price target on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Piper Sandler upped their price objective on Kenvue from $20.00 to $21.00 and gave the stock a “neutral” rating in a research note on Monday, September 23rd. JPMorgan Chase & Co. increased their target price on Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Kenvue has a consensus rating of “Hold” and an average price target of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.